On the Treatment of Prolapse of the Iris

The Role of Thyroid Stimulating Immunoglobulins of Graves's Disease in Neonatal Thyrotoxicosis

“…It is, thus, possible that the critical level of LATS-P in adults might be lower because it is sustained. The turnover rate of carbimazole, in particular, may be sufficiently slow to allow enough time for the TSIg to decline below the critical level and thus prevent any manifestation of neonatal thyrotoxicosis (Alexander et al, 1969;Ramsay, 1976;Munro et al, 1976). Another explanation for the apparent insensitivity of the fetal thyroid to LATS-P may be the difficulties in clinical and biochemical evidence of thyrotoxicosis in the neonatal period when normal infants show marked changes in thyroid function (Fisher and Sack, 1975).…”

“…Antithyroid drugs may cross the placenta and protect the newborn from the effects of TSIg. The turnover rate of carbimazole, in particular, may be sufficiently slow to allow enough time for the TSIg to decline below the critical level and thus prevent any manifestation of neonatal thyrotoxicosis (Alexander et al, 1969;Ramsay, 1976;Munro et al, 1976). There is a case reported of neonatal thyrotoxicosis in the absence of maternal Graves's disease (Thomson and Riley, 1966;Thomson et al, 1975) but the mother took iodide throughout pregnancy and had LATS-P in her serum almost ten years after delivery.…”

“…Studies of the rate of disappearance of LATS and LATS-P suggest half-lives of four to ten days (Maisey and Stimmler, 1972;Munro et al, 1976). Both fetal and neonatal thyrotoxicosis respond to antithyroid drugs Ramsay, 1976) and treatment can be continued until the TSIg levels have fallen below the critical value.…”